Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on August 3, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 results and provide a general business update. Interested parties can join by dialing 844-277-9450 (domestic) or 336-525-7139 (international), using conference ID 6519859. The company is a leader in microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results and receiving Breakthrough Therapy and Orphan Drug designations from the FDA for treating recurrent C. difficile infection.
- SER-109 program achieved first-ever positive pivotal clinical results for microbiome drug candidate.
- SER-109 has received Breakthrough Therapy and Orphan Drug designations from the FDA.
- None.
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m. ET to discuss second quarter 2021 results and provide a general business update.
To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6519859. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 in a Phase 1b study to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005160/en/
FAQ
When will Seres Therapeutics host its second quarter 2021 earnings call?
What is the conference ID for the Seres Therapeutics earnings call?
What are the key developments for Seres Therapeutics' SER-109 program?
How can I access the Seres Therapeutics earnings call?
